Back To: Home



A ‘transformative’ IRT solution for biotech and pharma sponsors
July 2017

WAYNE, Pa.—Bracket, a clinical trial technology and specialty services provider, announced June 1 the release of CUBE, what it calls “a transformative interactive response technology (IRT) solution for the life sciences industry.” CUBE is immediately available to qualifying biotechnology and pharmaceutical trial sponsors through Bracket.
The solution will reportedly enable biotech and pharmaceutical sponsors to utilize an innovative new solution to deploy studies in one to two weeks. It leverages an iterative user acceptance build experience to provide a rapid and advanced deployment methodology without the time and cost constraints of traditional IRT solutions. Key highlights of CUBE for biotech and pharma sponsors of any size include:
  • Accelerates times for sponsors and improves efficiency for contract research organizations (CROs)
  • Leverages Bracket's full randomization and trial supply management (RTSM) platform, but streamlines deployment through automation
  • Rapid project lifecycle lets sponsors experience the system prior to requirements approval
  • Reduces lengthy turnaround times for enhancements and in-study changes
“We’re so pleased to introduce CUBE to the life-sciences marketplace and are confident that its easy-to-implement nature will improve the process of managing clinical supplies,” said Jeff Kinell, CEO at Bracket. “By de-emphasizing requirement documents and prioritizing unique configuration needs, CUBE will undoubtedly evolve the paradigm of how sponsors collaborate to deploy IRT.”
Among the professed advantages of the platform is that it allows study teams to visualize the RTSM system during the kick-off meeting. This accelerates timelines for sponsors and improves efficiency for CROs. 



478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.